News Posts List
RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma
11/04/2015
We aimed to investigate whether expression in the primary tumour of genes involved in the development of BM is associated with outcome in m-ccRCC patients treated with anti-VEGFR-TKIs.
Arkadia-ESRP2 axis suppresses tumor progression
11/03/2015
Tumor-specific alternative splicing is implicated in the progression of cancer, including clear-cell renal cell carcinoma (ccRCC).
A CpG-methylation-based assay to predict survival
10/31/2015
Clear cell renal cell carcinomas (ccRCCs) display divergent clinical behaviours. Molecular markers might improve risk stratification of ccRCC.
Nintedanib Shows Promise For Advanced Renal Cell Carcinoma
10/17/2015
Post-hoc analysis suggested that nintedanib may have been particularly effective in patients with liver metastases at baseline, extending both PFS (8.4 vs 5.6 months) and OS (12.1 vs 8.2 months) compared with sunitinib.
Lenvatinib Phase II Results Show Significant Improvement in Progression-Free Survival When Used With Everolimus
10/16/2015
Phase II results show lenvatinib, when used in combination with everolimus, demonstrates significantly improved progression-free survival (PFS) versus everolimus alone in people with metastatic renal cell carcinoma (mRCC) following prior VEGF-targeted therapy.
Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
10/15/2015
This is a Phase II study to evaluate the efficacy and safety of savolitinib monotherapy (600 mg once daily) in papillary renal cell carcinoma (“PRCC”) in the United States, Canada and Europe. PRCC represents about 14% of all new cases of kidney cancer.
Gender differences in incidence and outcomes in kidney cancer.
10/08/2015
A gender discrepancy exists in the incidence of both urothelial and kidney carcinomas, with more men presenting with these cancers than women. Men have a threefold greater risk of developing bladder cancer than women, but female gender has been identified as an independent adverse prognostic factor for both recurrence and progression of this disease.
RCC trials don’t mirror real-world experience
10/06/2015
Researchers have found that real-world metastatic renal cell cancer patients being treated with tyrosine kinase inhibitors are often sicker than subjects in clinical trials for these drugs, leading to questions about safety for use in the very patients who need the drugs in clinical practice.
Cancer: Quality of Life vs. Survival
10/05/2015
We performed a cross-sectional survey of patients with cancer and HCPs to evaluate their perceptions about treatment priorities and to analyse variables that might influence their opinions. To identify treatment choices, we interviewed all participants using a structured questionnaire with fictitious case vignettes.
What we learned from Europe’s largest cancer conference
10/03/2015
We look back on some of the announcements from the European Cancer Conference in Vienna to highlight research which could make a big impact on cancer care and treatment.
News Feed